Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,993 Mln
P/E Ratio
25.83
P/B Ratio
3.92
Industry P/E
--
Debt to Equity
0.87
ROE
0.2 %
ROCE
9.2 %
Div. Yield
0 %
Book Value
14.08
EPS
2.17
CFO
$-2,762.99 Mln
EBITDA
$-3,340.74 Mln
Net Profit
$-3,963.14 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| -50.29 | -20.82 | -48.10 | -51.36 | -7.51 | -13.04 | 16.24 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| 25.85 | -25.58 | 43.90 | -47.18 | 32.12 | 18.24 | 95.42 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 58.42 | |
| 27.22 | 9,559.25 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers... EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Read more
President, CEO & Director
Mr. Douglas S. Ingram Esq.
President, CEO & Director
Mr. Douglas S. Ingram Esq.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sarepta Therapeutics Inc (DE) (SRPT) stood at $ 3,963 Mln as on 31-Dec-24
The share price of Sarepta Therapeutics Inc (DE) (SRPT) is $60.44 (NASDAQ) as of 25-Apr-2025 16:28 EDT. Sarepta Therapeutics Inc (DE) (SRPT) has given a return of -7.51% in the last 3 years.
Sarepta Therapeutics Inc (DE) (SRPT) has a market capitalisation of $ 5,993 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Sarepta Therapeutics Inc (DE) (SRPT) is 25.83 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sarepta Therapeutics Inc (DE) (SRPT) and enter the required number of quantities and click on buy to purchase the shares of Sarepta Therapeutics Inc (DE) (SRPT).
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
The CEO & director of Mr. Douglas S. Ingram Esq.. is Sarepta Therapeutics Inc (DE) (SRPT), and CFO & Sr. VP is Mr. Douglas S. Ingram Esq..
There is no promoter pledging in Sarepta Therapeutics Inc (DE) (SRPT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Sarepta Therapeutics Inc. (DE) (SRPT) | Ratios |
|---|---|
|
Return on equity(%)
|
19.71
|
|
Operating margin(%)
|
14.68
|
|
Net Margin(%)
|
12.37
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sarepta Therapeutics Inc (DE) (SRPT) was $0 Mln.
$-1.32
(
